{"entity":{"id":"nct05961839","kind":"trial","name":"Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","aka":[],"tldr":"A phase 1 trial of SGR-2921 run by Schrödinger, Inc., terminated.","summary":"Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1 interventional study registered as NCT05961839 by Schrödinger, Inc., with 66 participants enrolled, started 2023-09-27. Conditions recorded: Acute Myeloid Leukemia and High-Risk and Very High-Risk Myelodysplastic Syndromes. Interventions recorded: SGR-2921.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05961839","url":"https://clinicaltrials.gov/study/NCT05961839"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["sgr-2921"],"companies":["schrodinger"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05961839","phase":"1","setting":"A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"Schrödinger, Inc.","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05961839/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"drug":[{"id":"sgr-2921","kind":"drug","name":"SGR-2921","route":"/drugs/sgr-2921/"}],"company":[{"id":"schrodinger","kind":"company","name":"Schrödinger","route":"/companies/schrodinger/"}]}}